The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, Case–Control Study
Abstract
Background & aims Use of proton pump inhibitors (PPIs) has been associated with elevated levels of serum gastrin. Because hypergastrinemia increases colorectal mucosa proliferation and has been associated with risk of colorectal cancer (CRC) in human beings, we conducted a large population-based study in Denmark to assess whether PPI use is associated with CRC risk.Methods We conducted the study in North Jutland County, Denmark. From the County Hospital Discharge Registry we identified incident cases of CRC during the period 1989-2005. Using risk set sampling we selected approximately 10 controls from the Danish Civil Registration System, with matching for sex and birth year. PPI use was ascertained in the Prescription Database of North Jutland (and so recorded before CRC diagnosis) and analyzed with conditional logistic regression adjusted for multiple covariates.Results We identified 5589 cases of CRC which were compared with 55,890 controls. In a comparison of ever to never or rare users (< or =30 pills during observation period), no evidence was observed of increased risk (adjusted odds ratio [OR], 1.11; 95% confidence interval [CI], 0.97-1.27). When we compared the most intense users of PPI (more than every other day) with never or rare users, we found that no increased cancer risk was shown in either short-term users (adjusted OR, 1.07; 95% CI, 0.86-1.34) or long-term users (>7 years; adjusted OR = 1.09; 95% CI, 0.58-2.06).Conclusions The use of PPIs in clinical practice does not measurably increase the risk of CRC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, it is fundamental to highlight that many studies over the years have not found a direct correlation between PPI use in clinical practice and an increased risk of CRC[154-156].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [156]
Citations
Cites
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Epidemiology: Beyond the Basics
Szklo, M., & Nieto, F. J. (1999) · Cited by 1,441
Epidemiology: Beyond the Basics
Szklo, M. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.8.821 · Cited by 1,320
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,210
Selection of Controls in Case-Control Studies
Wacholder, S., McLaughlin, J. K., Silverman, D. T., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116396 · Cited by 998
The Danish prescription registries.
Gaist, D., Sørensen, H. T., & Hallas, J. (1997) · PubMed · Cited by 570
Self-citationApproaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine, L. (2001) · Gastroenterology · doi:10.1053/gast.2001.21907 · Cited by 551
A Comparison of Five Maintenance Therapies for Reflux Esophagitis
Vigneri, S., Termini, R., Leandro, G., Badalamenti, S., Pantalena, M., Savarino, V., Mario, F. D., Battaglia, G., Mela, G. S., Pilotto, A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331703 · Cited by 539
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 479
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G. M., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. J. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 368
Research works printed but not linked: 1
- Andersen, 1999, The Danish National Hospital Register, Dan Med Bull, 46, 263
Cited by
Sorted by citations
Freedberg, D. E., Kim, L. S., & Yang, Y. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 933
Control of Gastric Acid Secretion in Health and Disease
Schubert, M. L., & Peura, D. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.021 · Cited by 493
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. E. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Sheen, E., & Triadafilopoulos, G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1560-3 · Cited by 316
“Long-term PPI therapy at a regular dose was not associated with a significantly increased risk of CRC.”
BackgroundInfluentialProton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, . (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 290
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015
Iwakiri, K., Kinoshita, Y., Habu, Y., Oshima, T., Manabe, N., Fujiwara, Y., Nagahara, A., Kawamura, O., Iwakiri, R., Ozawa, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1227-8 · Cited by 284
Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
Kinoshita, Y., ISHIMURA, N., & Ishihara, S. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18001 · Cited by 274
“Two large independent observational studies investigated the risk of colon cancer during chronic administration of PPIs, and both found no evidence of increased risk.(144,145) Therefore, PPIs are considered not to increase the risk of colon cancer despite their association with elevated plasma gastrin levels.”
BackgroundProton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Proton pump inhibitors: Risks of long‐term use
Eusebi, L. H., Rabitti, S., Artesiani, M. L., Gelli, D., Montagnani, M., Zagari, R. M., & Bazzoli, F. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13737 · Cited by 217
Safety of Proton Pump Inhibitor Exposure
Yang, Y., & Metz, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.023 · Cited by 211
Long-term Safety Concerns with Proton Pump Inhibitors
Ali, T., Roberts, D. N., & Tierney, W. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.014 · Cited by 197
Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety
Savarino, V., Mario, F. D., & Scarpignato, C. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.016 · Cited by 185
Proton pump inhibitors and risk of gastric cancer: a population-based cohort study
Poulsen, A. H., Christensen, S., McLaughlin, J. K., Thomsen, R. W., Sørensen, H. T., Olsen, J. H., & Friis, S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605024 · Cited by 158
“…risk of gastric carcinoids, and gastric and colonic carcinomas (Havu, 1986; Laine et al, 2000; Gillen and McColl, 2001; Waldum et al, 2005; Kuipers, 2006), although recent results for PPI use and colorectal cancer risk are reassuring (Robertson et al, 2007; Yang et al, 2007; van Soest et al, 2008).”
ResultSelf-citationGenta, R. M., Schuler, C. M., Robiou, C., & Lash, R. H. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.015 · Cited by 133
Gardarsdóttir, H., Souverein, P. C., Egberts, T. C. G., & Heerdink, E. R. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.07.001 · Cited by 122
“When information on the dosage regimen is missing, the prescription duration is sometimes based on the amount of defined daily dose or number of pills dispensed [7,8].”
BackgroundSafety of long-term PPI therapy
Reimer, C. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.06.001 · Cited by 119
“This is consistent with data from the two other equally large studies from Denmark and the Netherlands [75,76] where PPI use for up to seven years did not increase the risk of CRC.”
BackgroundResultHvid‐Jensen, F., Pedersen, L. H., Funch-Jensen, P. M., & Drewes, A. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12693 · Cited by 102
“fied as short term (<7 years) or long term (>7 years), based on the number of days between the first and last prescription dates, as done in previous studies.(23) We also did calculations using 5 years as cut-off point yielding minimal differences in risk estimates (data not”
BackgroundMethodInfluentialSelf-citationLee, J. K., Merchant, S. A., Schneider, J. L., Jensen, C. D., FIREMAN, B. H., Quesenberry, C. P., & Corley, D. A. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000591 · Cited by 91
Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis
Islam, M. M., Poly, T. N., Walther, B. A., Dubey, N. K., Anggraini Ningrum, D. N., Shabbir, S.-A., & (Jack) Li, Y.-C. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001198 · Cited by 88
Epidemiology of colorectal cancer in Asia
Yee, Y. K., Tan, V. P., Chan, P., Hung, I. F., Pang, R. W. C., & Yu, W. B. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06138.x · Cited by 83
Proton Pump Inhibitors and the Risk of Colorectal Cancer
van Soest, E. M., van Rossum, L. G. M., Dieleman, J. P., van Oijen, M. G. H., Siersema, P. D., Sturkenboom, M. C. J. M., & Kuipers, E. J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01665.x · Cited by 80
Dacha, S., Razvi, M., Massaad, J., Cai, Q., & Wehbi, M. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov004 · Cited by 97
Potential adverse effects of proton pump inhibitors
Coté, G. A., & Howden, C. W. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0045-4 · Cited by 69
Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis
Freeman, H. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1318 · Cited by 69
Long-term proton pump inhibitor use and gastrointestinal cancer
Graham, D. Y., & Genta, R. M. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0100-1 · Cited by 67
Subramaniam, D., Ramalingam, S., May, R. J., Dieckgraefe, B. K., Berg, D. E., Pothoulakis, C., Houchen, C. W., Wang, T. C., & Anant, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.040 · Cited by 68
Prescribing Proton Pump Inhibitors
Vakil, N. B. (2012) · Drugs · doi:10.2165/11599320-000000000-00000 · Cited by 64
“Population-based studies do not suggest an association between PPI use and colon cancer.([32,33]) 440 Vakil”
Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus
Wang, J. S., Varró, A., Lightdale, C. J., Lertkowit, N., Slack, K. N., Fingerhood, M., Tsai, W. Y., Wang, T. C., & Abrams, J. A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.629 · Cited by 58
Proton pump inhibitors and risk of colorectal cancer
Abrahami, D., McDonald, E. G., Schnitzer, M. E., Barkun, A. N., Suissa, S., & Azoulay, L. (2021) · Gut · doi:10.1136/gutjnl-2021-325096 · Cited by 56
Proton pump inhibitors on pancreatic cancer risk and survival
Kearns, M. D., Boursi, B., & Yang, Y. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2016.12.006 · Cited by 56
When does proton pump inhibitor treatment become long term? A scoping review
Haastrup, P., Jarbøl, D. E., Thompson, W., Hansen, J. M., Søndergaard, J., & Rasmussen, S. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000563 · Cited by 55
Gastrin, Helicobacter pylori, and Colorectal Adenomas
Robertson, D. J., Sandler, R. S., Ahnen, D. J., Greenberg, E. R., Mott, L. A., Cole, B. F., & Baron, J. A. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.09.006 · Cited by 50
Self-citationKim, Y. J., Lee, J. S., Hong, K. S., Chung, J. W., Kim, J. H., & Hahm, K. B. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0033 · Cited by 50
“However, the use of PPIs in clinical practice does not measurably increase the risk of colorectal cancer (26, 27), supporting our results that the trophic actions of increased gastrin also could be blocked with PPI.”
ResultEffects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer
Wong, G. L., Ha, V., Chu, M. P., Dersch‐Mills, D., Ghosh, S., Chambers, C. R., & Sawyer, M. B. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.001 · Cited by 50
Lei, W., Wang, J., Yi, C., Liu, T., Hung, J., Wong, M., Bair, M., Vaezi, M. F., Orr, W. C., & Chen, C. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.02.017 · Cited by 48
Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies
Ahn, J. S., Park, S. M., Eom, C.-S., Kim, S., & Myung, S. (2012) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2012.33.5.272 · Cited by 44
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
Deva, S., & Jameson, M. B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007814.pub2 · Cited by 44
Sawaid, I. O., & Samson, A. O. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071970 · Cited by 42
“The study showed that long-term PPI use was not associated with an increased risk of colorectal cancer among those who had used PPIs for more than 7 years compared to those who had never used them [32].”
BackgroundHeidelbaugh, J. J., Metz, D. C., & Yang, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02921.x · Cited by 42
Is There a Dark Side to Long-term Proton Pump Inhibitor Therapy?
Nealis, T. B., & Howden, C. W. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817149bf · Cited by 41
Colorectal cancer risk in relation to use of acid suppressive medications
Chubak, J., Boudreau, D. M., Rulyak, S. J., & Mandelson, M. T. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1749 · Cited by 40
Bradley, M. C., Murray, L., Cantwell, M. M., & Hughes, C. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.511 · Cited by 37
“However, increased incidence, along with the higher mortality rates for oesophageal cancer, was attributed to the underlying disease and not to treatment with PPIs (Bateman et al , 2003; Garcı´a Rodrı´guez et al , 2006); Robertson et al , 2007).”
BackgroundHwang, I. C., Chang, J., & Park, S. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189114 · Cited by 36
Schneider, J. L., Kolitsopoulos, F. M., & Corley, D. A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13450 · Cited by 34
Cronin-Fenton, D. P., Pedersen, L. H., Lash, T. L., Friis, S., Baron, J. A., & Sørensen, H. T. (2010) · Breast Cancer Research · doi:10.1186/bcr2482 · Cited by 34
“[76].”
Self-citationHypergastrinemia in Long-Term Use of Proton Pump Inhibitors
Shiotani, A., Katsumata, R., Gouda, K., Fukushima, S., Nakato, R., Murao, T., Ishii, M., Fujita, M., Matsumoto, H., & Sakakibara, T. (2018) · Digestion · doi:10.1159/000484688 · Cited by 33
Teixeira, M. Z. (2011) · Homeopathy · doi:10.1016/j.homp.2011.05.003 · Cited by 34
Joo, M. K., Park, J., & Chun, H. J. (2017) · Digestive Diseases · doi:10.1159/000480149 · Cited by 30
Kao, W., Su, C., Tan, E. C., Lee, P., Chen, P., Tang, J., Huang, Y., Huo, T., Chang, C., Hou, M., et al. (2018) · Hepatology · doi:10.1002/hep.30247 · Cited by 28
“(29) However, three large case–control studies failed to identify a positive correlation between the use of PPIs and the risk of developing colon cancer.(30-32) Regarding liver tumors, one recent study from the US veterans database revealed that PPI use is associated with an increased risk of cirrhosis, hepatic decomp…”
BackgroundBabić, A., Zhang, X., Morales‐Oyarvide, V., Yuan, C., Khalaf, N. I., Khalili, H., Lochhead, P. J., Chan, A. T., Ogino, S., Wolpin, B. M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0939-y · Cited by 27
Guo, H., Zhang, R., Zhang, P., Chen, Z., Hua, Y., Huang, X., & Li, X. F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1129948 · Cited by 28
“Eventually, 22 eligible articles were included in our analysis (Garcia Rodriguez et al., 2006; Robertson et al., 2007; Yang et al., 2007; Tamim et al., 2008; van Soest et al., 2008; Chubak et al., 2009; Poulsen et al., 2009; Lai et al., 2013; Hwang et al., 2017; Wennerström et al., 2017; Cheung et al., 2018; Niikura e…”
BackgroundHan, Y., Hahm, K. B., Park, J., Hong, S. P., & Kim, E. (2014) · Neoplasia · doi:10.1593/neo.131510 · Cited by 26
“However, a recent clinical study of a large-scale cohort and prospective investigation reported that hypergastrinemia following long-term PPI therapy at a regular dose is not associated with an increased risk of colorectal cancer [4].”
BackgroundInfluentialSingh, M., Dhindsa, G., Friedland, S., & Triadafilopoulos, G. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03450.x · Cited by 26
Obszynska, J., Atherfold, P. A., Nanji, M. S., Glancy, D., Santander, S., Graham, T. A., Otto, W. R., West, K., Harrison, R. F., & Jankowski, J. A. (2009) · Gut · doi:10.1136/gut.2009.186775 · Cited by 26
Ma, T., Wu, M., Jia, S., & Yang, L. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03717-5 · Cited by 24
Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers
Zeng, R., Cheng, Y., Luo, D., Wang, J., Yang, J. H., Jiang, L., Zhuo, Z., Guo, K., Wu, H., Leung, F. W., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.030 · Cited by 24
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Koulouridi, A., Messaritakis, I., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2020) · Cancers · doi:10.3390/cancers13010043 · Cited by 26
Indications and safety of proton pump inhibitor drug use in patients with cancer
Triadafilopoulos, G., Roorda, A. K., & Akiyama, J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.797961 · Cited by 23
“Thorburn et al. [102] later conducted a case--control study using stored sera from the 1960s in a large cohort of patients subsequently followed for development of CRC. Baseline gastrin levels above normal were associated with increased risk for colorectal malignancy (OR, 3.9; 95% CI, 1.5 -- 9.6).”
BackgroundInfluentialHálfdánarson, Ó., Fall, K., Ogmundsdottir, M. H., Lund, S. H., Steingrı́msson, E., Ogmundsdottir, H. M., & Zoëga, H. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4702 · Cited by 22
Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer
Morton, M. F., Prendergast, C. E., & Barrett, T. D. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.003 · Cited by 22
The clinical safety of long‐term lansoprazole for the maintenance of healed erosive oesophagitis
Freston, J. W., Hisada, M., Peura, D. A., Haber, M. M., Kovacs, T. O. G., Atkinson, S. N., & Hunt, B. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03998.x · Cited by 22
Chang, E. T., Cronin-Fenton, D. P., Friis, S., Hjalgrim, H., Sørensen, H. T., & Pedersen, L. H. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0909 · Cited by 21
“Intensity of use was defined as low (<25%) or medium/high (≥25%) according to the number of days of prescription coverage divided by duration of use in days (12).”
BackgroundMethodSelf-citationRobertson, D. J., Riis, A. H., Friis, S., Pedersen, L. H., Baron, J. A., & Sørensen, H. T. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.08.010 · Cited by 21
Self-citationWang, X., Liu, Q., Hálfdánarson, Ó., Zoëga, H., Sadr‐Azodi, O., Engstrand, L. G., Fall, K., & Brusselaers, N. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01480-0 · Cited by 20
Chang, E. T., Frøslev, T., Sørensen, H. T., & Pedersen, L. H. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.443 · Cited by 19
“%) users, based on the estimated total number of days of prescription coverage (using the assumption of 30 days per prescription, on average) divided by the duration of use in days (Robertson et al, 2007).”
BackgroundSelf-citationA Retrospective Analysis of the Role of Proton Pump Inhibitors in Colorectal Cancer Disease Survival
Graham, C. H., Orr, C., Bricks, C. S., Hopman, W. M., Hammad, N., & Ramjeesingh, R. (2016) · Current Oncology · doi:10.3747/co.23.3204 · Cited by 19
Song, H. J., Jeon, N., & Squires, P. J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02927-8 · Cited by 19
Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren
von Rahden, B. H. A., Scheurlen, M., Filser, J., Stein, H. J., & Ct, G. (2011) · Der Chirurg · doi:10.1007/s00104-011-2173-x · Cited by 19
Risk of Colorectal Cancer in Patients With Barrett's Esophagus: A Dutch Population-Based Study
de Jonge, P. J. F., BLANKENSTEIN, M. V., Looman, C. W. N., Casparie, M. K., Meijer, G. A., & Kuipers, E. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.503 · Cited by 19
Pantoprazole, a proton pump inhibitor, increases orthodontic tooth movement in rats.
Shirazi, M., Alimoradi, H., Kheirandish, Y., Etemad‐Moghadam, S., Alaeddini, M., Meysamie, A., Meybodi, S. A. R. F., & Dehpour, A. R. (2014) · Europe PMC (PubMed Central) · Cited by 18
Teixeira, M. Z. (2012) · Cited by 17
Use of proton pump inhibitors and the risk of hepatocellular carcinoma
Chang, T.-E., Huang, Y., Perng, C., Huang, Y., & Hou, M. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000157 · Cited by 16
Clinical significance of P‑class pumps in cancer (Review)
Themistocleous, S., Yiallouris, A., Tsioutis, C., Zaravinos, A., Johnson, E. O., & Patrikios, I. S. (2021) · Oncology Letters · doi:10.3892/ol.2021.12919 · Cited by 16
Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps
Hsu, W., Wu, I., Kuo, C., Su, Y., Lu, C., Kuo, F., Jan, C., Wang, W., Wu, D., & Yu, F. (2010) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/s1607-551x(10)70011-5 · Cited by 15
Han, Y.-M., Park, J., Park, S.-H., Hahm, K. B., Hong, S. P., & Kim, E.-H. (2013) · PubMed · Cited by 15
Zhang, W., Wu, J., & Atkinson, S. N. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008330155 · Cited by 14
“Although elevated gastrin levels have been associated with cancer, these associations appear to be independent of PPI use and may be attributable to other mechanisms.(33,42) No endocrine dysplasia, neoplasia, or carcinoid development attributable to hypergastrinemia has been reported in any PPI studies, including thos…”
BackgroundCirculating gastrin concentrations in patients at increased risk of developing colorectal carcinoma
Paterson, A. C., Macrae, F., Pizzey, C., Baldwin, G. S., & Shulkes, A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12417 · Cited by 13
Proton pump inhibitors and colorectal cancer: A systematic review
Patel, A., Spychalski, P., Antoszewska, M., Reguła, J., & Kobiela, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i44.7716 · Cited by 12
Liu, K., Wang, Y., Wang, J., Chen, B., Luo, N., & Gong, J. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001418 · Cited by 11
Proton pump inhibitors are not associated with an increased risk of colorectal cancer
Kuiper, J. G., van Herk‐Sukel, M. P. P., Lemmens, V. E. P. P., Kuipers, E. J., & Herings, R. M. C. (2020) · GastroHep · doi:10.1002/ygh2.409 · Cited by 11
Atrophic gastritis and the risk of incident colorectal cancer
Laiyemo, A. O., Kamangar, F., Marcus, P. M., Taylor, P. R., Virtamo, J. R. K., Albanes, D., & Stolzenberg‐Solomon, R. Z. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9446-4 · Cited by 10
“However, based on prescription information, recent studies did not find an increased risk of colorectal cancer with PPI use, [9–12] but the duration of PPI exposures in these studies were relatively short given the long time period required for colorectal cancer to develop from a normal mucosa.”
Long-Term Acid Inhibition: Benefits and Harms
Tepeš, B. (2011) · Digestive Diseases · doi:10.1159/000331519 · Cited by 9
Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren: Argumente Pro Fundoplicatio bei GERD?
von Rahden, B. H. A., Scheurlen, M., Filser, J., Stein, H. J., & Germer, C.-T. (2012) · Der Chirurg · Cited by 9
Similia similibus curentur: o princípio de cura homeopático fundamentado na farmacologia moderna
Teixeira, M. Z. (2013) · Revista de Medicina · doi:10.11606/issn.1679-9836.v92i3p183-203 · Cited by 13
Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line
Ellrichmann, M., Ritter, P. R., Schrader, H., Schmidt, W. E., Meier, J. J., & Schmitz, F. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.06.004 · Cited by 9
Proton pump inhibitors: concerns over prolonged use.
Mouli, V. P., & Ahuja, V. (2011) · PubMed · Cited by 8
Campos, D. A., Lima, A. F., Ribeiro, S. R. L., Silveira, E. R., Pessoa, O. D. L., Rao, V. S. N., & Santos, F. A. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.3.0016 · Cited by 8
“It has been firmly established that oxidative stress and impaired prostaglandin synthesis contribute to gastric mucosal damage in experimental models of gastric lesions induced by both ethanol and indometacin (Kwiecien et al 2002; Chattopadhyay et al 2006; Robertson et al 2007).”
BackgroundCardona-Ospina, J. A., Medina-Morales, D. A., Rodriguez-Morales, A. J., & Machado‐Alba, J. E. (2017) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.115 · Cited by 8
Proton pump inhibitors: use, misuse and concerns about long-term therapy
Rakesh, T. P. (2011) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-011-0208-y · Cited by 7
Inhibiteurs de la pompe à protons (IPP) et cancers : une association à risques ?
Raoul, J., Edeline, J., Gilabert, M., Senellart, H., & Frenel, J. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.12.009 · Cited by 6
Sawaid, I. O., Din, Z., Golan, E., Ruppin, E., Golan‐Cohen, A., Green, I., Merzon, E., Vinker, S., Samson, A. O., & Israel, A. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004842 · Cited by 5
“Nevertheless, the association between PPI use and gastric cancer remains controversial [28,29].”
Amano, Y., Nakahara, R., Yuki, T., Murakami, D., Ujihara, T., Tomoyuki, I., Sagami, R., Suehiro, S., Katsuyama, Y., Hayasaka, K., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01600-x · Cited by 5
Pregnancy in a liver transplant patient treated with everolimus and tacrolimus
Ciortea, R., Ciobanu, L., Matei, E., Zanfi, C., & Blaga, L. D. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3181 · Cited by 5
Gastroesophageal Reflux Disease
Roman, S., Pandolfino, J. E., & Kahrilas, P. J. (2015) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781118512074.ch49 · Cited by 5
Kwon, M. J., Han, K. M., Kim, J., Kim, J. H., Kim, M.-J., Kim, N. Y., Choi, H. G., & Kang, H. S. (2023) · Cancers · doi:10.3390/cancers15235606 · Cited by 4
“Most previous studies regarding the association between PPI use and CRC probability were conducted in non-Asian countries [16–18,28 –30 We hypothesized that a history of prior PPI exposure and the duration of use could adversely induce the development of CRC and that there might be specific risk…”
InfluentialPop, C. S., Preda, C. M., Mănuc, M., Gheorghe, L. S., Istrătescu, D., Chifulescu, A. E., Voiosu, T. A., Diculescu, M., Ţieranu, C. G., & Iliescu, L. E. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3148 · Cited by 3
Metadata
- Authors
- Robertson, D. J., Larsson, H., Friis, S., Pedersen, L., Baron, J. A., & Sørensen, H. T.
- Affiliations
- Dartmouth–Hitchcock Medical Center (US)
- Aarhus University Hospital (DK)
- Danish Cancer Society (DK)
- Corresponding author
- Robertson, Douglas J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 133
- Issue
- 3
- Pages
- 755-760
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1977659216
- Cited by
- 139
- References
- 51
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 9 · 2020: 17 · 2019: 3 · 2018: 7 · 2017: 10 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 8
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Keywords
- proton pump inhibitors, colorectal cancer, hypergastrinemia, serum gastrin, cancer risk, drug use, long-term PPI use
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Denmark, Dose-Response Relationship, Drug, Female, Gastrins, Histamine H2 Antagonists, Humans, Hypoglycemic Agents, Intestinal Mucosa, Male, Risk Factors, Time Factors, Colorectal Neoplasms, Logistic Models, Case-Control Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cell Proliferation, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
